The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Editorials

Items, Instruments, Crosswalks, and PROMIS
J.F. Fries, E. Krishnan, B. Bruce ........................................... 1093

“KISS” — Embracing Routine Patient Assessment
T. Uhlig ................................................................. 1096

Quantitative Clinical Rheumatology: “Keep It Simple, Stupid”: Multidimensional Health Assessment Questionnaire Function, Pain, Global, and Routine Assessment of Patient Index Data 3 Quantitative Scores to Improve and Document the Quality of Rheumatologic Care T. Pincus, T. Sokka … 1099

Moving Up the Pyramid: Assessing Performance in the Clinic S. Aaron ..................................................... 1101

Very Early Intervention Is Crucial to Improve Work Outcome in Patients with Rheumatoid Arthritis
K. Eberhardt ................................................................. 1103

Biologic Agents in the Treatment of Rheumatic Diseases with Chronic Viral Infection. Where Are We?
D. Wendling, V. Di Martino, G. Herbein ............................. 1107

Reviews

Land-based Exercise for Osteoarthritis of the Knee: A Metaanalysis of Randomized Controlled Trials
M. Fransen, S. McConnell ................................................. 1109

Anakinra for Rheumatoid Arthritis: A Systematic Review
M. Mertens, J.A. Singh ..................................................... 1118

Articles

High Serum COMP Determines the Subset of Patients with Early-Stage RA with High Serum CRP, MMP-3, and MRI-Proven Bone Erosion

Immunogenetic Risks of Anti-CCP Antibodies in a North American Native Population with RA and Their First-degree Relatives

The Role of Anti-Mutated Citrullinated Vimentin Antibodies in the Diagnosis of Early RA X. Liu, R. Jia, J. Zhao, Z. Li … 1136

The Value of HLA-DRB1 Shared Epitope, −308 TNF-α Gene Promoter Polymorphism, Rheumatoid Factor, Anti-CCP, and Early Erosions for Predicting Radiological Outcome in Recent-Onset RA S. Reneses, M.F. González-Escribano, A. Fernandez-Suárez, et al .................. 1143

Validating and Assessing the Sensitivity of the HAQ-DI-derived SF-6D in Patients with Early Aggressive RA
S.S. Amjadi, P.M. Maranian, H.E. Paulus, et al, for the Western Consortium of Practicing Rheumatologists ................................. 1150

Correlation of CX3CL1 and CX3CR1 Levels with Response to Infliximab Therapy in Patients with RA
T. Odai, M. Matsunawa, R. Takahashi, et al ......................... 1158

Differences in Longitudinal Disease and Treatment Characteristics of Patients with RA Replying and Not Replying to a Postal Questionnaire. Experience from a Biologics Register in Southern Sweden

Sick Leave Before and After Diagnosis of RA — a Report from the Swedish TIRA Project
M. Björk, I. Thyberg, K. Flikner, I. Balogh, B. Gerdle .......................... 1170

Relationship Between Pack-year History of Smoking and Response to TNF Antagonists in Patients with RA
D.L. Mattrey, A. Brownfield, P.T. Dawes ............................. 1180

Use of TNF-α-blocking Agents in HBV-positive Patients: Reports of 3 Cases and Review of the Literature
S. Zingarelli, M. Frassi, C. Bazzani, M. Scarsi, M. Puoti, P. Aiò .......................... 1188

Determinants of Risk for Venous and Arterial Thrombosis in Primary and Secondary APS and Lupus Erythematosus: A Cross-sectional Study
A. Danowski, M.N.L. de Azevedo, J.A. de Souza Papi, M. Petri .................. 1195

The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multietnic Cohort
C.A. Peschken, D. Karpman, M. Carmona, et al, for the Canadian Lupus Network ................................. 1200

Psychometric Properties of the EuroQol-5D and SF-6D in Patients with SLE
R. Aggarwal, C. Wilke, A.S. Pickard, et al ............................. 1209

Quantitative Abnormalities of Peripheral Blood Distinct T, B, and Natural Killer Cell Subsets and Clinical Findings in Obstetric APS
J. Carbone, A. Gallego, N. Lanio, et al ............................. 1217

Clinical Correlates of Self-reported Physical Health Status in SSc
M. Hudson, R. Steele, Y. Lu, B.D. Thoms, P. Panopalis, M. Baron, for the Canadian Scleroderma Research Group ............................. 1226

HLA-G Expression in the Skin of Patients with SSc

Raynaud’s Phenomenon and Plasma Endothelin: Correlations with Capillaroscopic Patterns in SSc
A. Sulli, S. Soldano, C. Pizzorni, et al ............................. 1235

Immunological Reconstitution After Autologous Hematopoietic Stem Cell Transplant in Patients with SSc: Clinical Benefits and Intensity of Immunosuppression
T. Bohgaki, T. Atsumi, M. Bohgaki, et al ............................. 1240

Contents continued opposite inside back cover...
Spinal Radiographic Changes in AS: Association with Clinical Characteristics and Functional Outcome
A. Boonen, B. vander Cruyssen, K. de Vlam, et al. 1249

Etanercept in the Longterm Treatment of Patients with AS
B. Dijkmans, P. Emery, M. Hakala, et al. 1256

The CPPDD-Associated ANKH M48T Mutation Interrupts the Interaction of ANKH with the Sodium/Phosphate Cotransporter PIT-1
J. Wang, H.W. Tsui, F. Beier, F.W.L. Tsui. 1265

Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout
M.A. Becker, H.R. Schumacher, P.A. MacDonald, E. Lloyd, C. Lademacher. 1273

Poor Validation of Medical Record ICD-9 Diagnoses of Gout in a Veterans Affairs Database
A. Malik, J.E. Dinnella, C.K. Kwoh, H.R. Schumacher. 1283

Serum Urate During Acute Gout
N. Schlesinger, J.M. Norquist, D.J. Watson. 1287

Efficacy, Safety, and Tolerability of the Cyclooxygenase-Inhibiting NO Donator Naproxcinod in Treating OA of the Hip or Knee
J. Karlsson, A. Pivodic, D. Aguirre, T.J. Schnitzer. 1290

Resident Evaluations: The Use of Daily Evaluation Forms in Rheumatology Ambulatory Care
S. Humphrey-Murto, N. Khalidi, C.D. Smith, et al. 1298

Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire
R.M. Bennett, A.G. Bushmakin, J.C. Cappelleri, G. Zlateva, A.B. Sadosky. 1304

Meeting Report 13th International Conference on Behçet’s Disease, May 24-27, 2008, Pörtschach am Wörthersee, Austria
C. Dejaco, C. Duftner, K.T. Calamia, M. Schirmer. 1312

Pediatric Rheumatology
The Hypoxic Synovial Environment Regulates Expression of VEGF and Osteopontin in JIA
M.C. Bosco, S. Delfino, F. Ferlito, et al. 1318

HRQOL, Physical Function, Fatigue, and Disease Activity in Children with Established Polyarticular JIA
S. Ringold, C.A. Wallace, F.P. Rivara. 1330

Effect of Musculoskeletal Pain on Sexuality of Male Adolescents and Adults with JIA

Images in Rheumatology
Glomus Tumor
A. Espinosa-Gutierrez, A. Izaguirre, L. Baena-Ocampo, F. Pineda. 1343

Correspondence
Let’s Talk About Sex!
C. Bidwell, I. Bolt, J.E. McDonagh. 1345

Reply
M. Kaufman, R.F. Spitzer. 1345

Increased Adiponectin Levels in Women with RA After Etanercept Treatment
M. Lewicki, P. Kotyla, E. Kucharz. 1346

Reply
T. Nagashima, S. Minota. 1347

Whiplash and the Turtle
A.S. Russell, R. Ferrari. 1348

Reply
M. Harth. 1348

Letters
Etanercept Treatment in Sweet’s Syndrome with Inflammatory Arthritis
N.L. Ambrose, A.M. Tobin, D. Howard. 1348

Longstanding Remission of AOSD Under Imatinib Therapy in a Patient with Chronic Myelogenous Leukemia
Y. Nagasaki, T. Miyamoto, H. Hazy, M. Harada, K. Akashi. 1349

Book Review
Arthritis: How to Stay Active and Relieve Your Pain. 1351

Correction
Autoantibody and Biopsy Grading Are Associated with Expression of ICAM-1, MMP-3, and TRAIL in Salivary Gland Mononuclear Cells of Chinese Patients with Sjögren’s Syndrome

Meetings in Rheumatology
xiv